HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HHS First Stop For External Review Of US FDA’s Planned Human Foods Program Reorganization

Executive Summary

FDA says plan forwarded for review by Department of Health and Human Services to start “formal external review process.” After “several critical steps” which would follow HHS sign-off, FDA expects to implement unified Human Food Program during 2024.

You may also be interested in...



FDA Food Programs Chief Assured On Supplement Office Move, Pessimistic On Agency Budget

“We think that this structure actually provides us the best path forward in terms of optimizing on our resources,” Jim Jones says of ODSP move. On the other hand, he says Congress didn’t appropriate for the agency’s optimal operation.

In Proposed Appropriation, Congress Tells FDA To Repurpose $7M For Cosmetic Regulation

Proposed budget agreement by House and Senate leaders comes four days before funding ends under the latest continuing resolution to keep the federal government open and a week before the White House plans to release its FY2025 budget request.

Good ‘Fit’ For Regulation Shifting US FDA's ODSP Into Larger Food Safety Program – Director

ODSP Director Cara Welch spoke about food programs structure and other supplement industry regulatory news days before first day on the job for agency’s first deputy commissioner for human foods, a post added in the human foods reorganization plan.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154267

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel